Non-alcoholic fatty liver disease (NAFLD) is caused by an accumulation of fat in the liver; the
condition can progress over time to increase the risk of develo** cirrhosis, end-stage liver …

Diabetic nephropathy is the leading cause of end-stage renal disease. Patients with diabetic
nephropathy have a high cardiovascular risk, comparable to patients with coronary heart …

Diabetic kidney disease (DKD) occurs in 25%-40% of patients with diabetes. Given the dual
problems of a significant risk of progression from DKD to end-stage renal disease (ESRD) …

Atualmente, é amplamente aceita a definição da doença renal crônica (DRC) que se baseia
em alterações na taxa de filtração glomerular e/ou presença de lesão parenquimatosa …

Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and
glycemia in accordance with current standards of care, patients with dyslipidemia remain at …

Aims/hypothesis Fenofibrate caused an acute, sustained plasma creatinine increase in the
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control …

When the'lipid nephrotoxicity hypothesis' was proposed in 1982, it brought together several
disparate experimental findings in hyperlipidemia and renal disease to suggest that …

Background The effects of statin administration on kidney disease outcomes remain
controversial. We undertook a systematic review and meta-analysis to assess the efficacy of …

Objectives: This subanalysis of the TNT (Treating to New Targets) study investigates the
effects of intensive lipid lowering with atorvastatin in patients with coronary heart disease …

Background The role of lipid-lowering treatments in renoprotection for patients with diabetes
is debated. We studied the renal effects of two statins in patients with diabetes who had …